Immunologic disparities in prostate cancer between American men of African and European descent

Abraham-Miranda, Julieta; Awasthi, Shivanshu; Yamoah, Kosj

doi:10.1016/j.critrevonc.2021.103426

Cited by 3 publications

(3 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Black men with local-stage disease face a higher risk of progression after treatment . Many explanations have been proposed, with various molecular, genetic, environmental, and even psychological factors suggested as causes of these disparities …”

Section: Introductionmentioning

confidence: 99%

“…12 Many explanations have been proposed, with various molecular, genetic, environmental, and even psychological factors suggested as causes of these disparities. [13][14][15][16][17][18][19][20][21][22][23] Prostate cancer is a notably heterogeneous disease, with the implications for a patient's quality of life, survival, and need and type of treatment all depending on the disease stage and biological characteristics. Patients with newly diagnosed low-risk disease can be simply monitored for disease progression; this approach spares them from the adverse effects of treatment without affecting their survival.…”

Section: Introductionmentioning

confidence: 99%

“… 12 Many explanations have been proposed, with various molecular, genetic, environmental, and even psychological factors suggested as causes of these disparities. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer

Rasmussen,

Patil,

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceRacial and ethnic disparities in prostate cancer are poorly understood. A given disparity-related factor may affect outcomes differently at each point along the highly variable trajectory of the disease.ObjectiveTo examine clinical outcomes by race and ethnicity in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) within the US Veterans Health Administration.Design, Setting, and ParticipantsA retrospective, observational cohort study using electronic health care records (January 1, 2006, to December 31, 2021) in a nationwide equal-access health care system was conducted. Mean (SD) follow-up time was 4.3 (3.3) years. Patients included in the analysis were diagnosed with prostate cancer from January 1, 2006, to December 30, 2020, that progressed to nmCRPC defined by (1) increasing prostate-specific antigen levels, (2) ongoing androgen deprivation, and (3) no evidence of metastatic disease. Patients with metastatic disease or death within the landmark period (3 months after the first nmCRPC evidence) were excluded.Main Outcomes and MeasuresThe primary outcome was time from the landmark period to death or metastasis; the secondary outcome was overall survival. A multivariate Cox proportional hazards model, Kaplan-Meier estimates, and adjusted survival curves were used to evaluate outcome differences by race and ethnicity.ResultsOf 12 992 patients in the cohort, 826 patients identified as Hispanic (6%), 3671 as non-Hispanic Black (28%; henceforth Black), 7323 as non-Hispanic White (56%; henceforth White), and 1172 of other race and ethnicity (9%; henceforth other, including American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, unknown by patient, and patient declined to answer). Median time elapsed from nmCRPC to metastasis or death was 5.96 (95% CI, 5.58-6.34) years for Black patients, 5.62 (95% CI, 5.11-6.67) years for Hispanic patients, 4.11 (95% CI, 3.96–4.25) years for White patients, and 3.59 (95% CI, 3.23-3.97) years for other patients. Median unadjusted overall survival was 6.26 (95% CI, 6.03-6.46) years among all patients, 8.36 (95% CI, 8.0-8.8) years for Black patients, 8.56 (95% CI, 7.3-9.7) years for Hispanic patients, 5.48 (95% CI, 5.2-5.7) years for White patients, and 4.48 (95% CI, 4.1-5.0) years for other patients.Conclusions and RelevanceThe findings of this cohort study of patients with nmCRPC suggest that differences in outcomes by race and ethnicity exist; in addition, Black and Hispanic men may have considerably improved outcomes when treated in an equal-access setting.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer

Rasmussen,

Patil,

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

Prostate cancer metastasis and health disparities: a systematic review

Liadi

Campbell

Dike

et al. 2023

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The association between sexual dysfunction and prostate cancer: a systematic review and meta-analysis

Dilixiati

Kadier

Laihaiti

et al. 2023

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Background Whether there is a connection between sexual dysfunction (SD) and prostate cancer (PCa) is controversial. Aim We sought to review the interrelationship between SD and PCa and to determine whether there is a definitive risk of men developing PCa after suffering from SD. Methods A complete search of the PubMed, Web of Science, Ovid MEDLINE, Embase, and Cochrane Library databases was performed to search for eligible studies published up to October 2022. The protocol for this meta-analysis is available from PROSPERO (ID: CRD42022342381). Outcomes The associations between SD and the risk of PCa were assessed by calculating pooled ORs with 95% CIs, and the standard mean difference (SMD) and its 95% CI were used to assess the relationship between SD and prostate-specific antigen (PSA) levels or prostate volume (PV). Random-effects models were used to account for potential heterogeneity, and the Newcastle–Ottawa Scale (NOS) was used to evaluate the quality of the included studies. Results Twenty studies involving 215,626 individuals were included in our meta-analysis. Compared with controls, subjects with SD had a 1.62-fold increased risk of PCa (OR = 1.62, 95% CI, 1.77-2.23, P = .003; heterogeneity: I2 = 97.8%, P < .001). Patients with SD had higher PSA levels than controls (SMD =0.07, 95% CI, 0.00 to 0.13, P = .041; heterogeneity: I2 = 55.6%, P = .027). However, there was no association between SD and PV (SMD = 0.03, 95% CI, −0.05 to 0.11, P = .122; heterogeneity: I2 = 48.5%, P = .100). Clinical Implications Current evidence confirms a potential link between SD and the risk of PCa and that SD in PCa patients should be of concern to clinicians. Strengths and Limitations The strength of this study is that it is to our knowledge the first meta-analysis of studies on the risk of PCa in men with SD. A limitation is that most of the studies included in this meta-analysis focused on ED. Conclusion Our systematic review and meta-analysis results suggest that men with SD have a higher risk of PCa and higher PSA levels than men without SD. However, this is merely inferential, and causality cannot be determined based on the current data. Further longitudinal studies should be performed to validate our preliminary findings.

show abstract

Immunologic disparities in prostate cancer between American men of African and European descent

Cited by 3 publications

References 97 publications

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer

Prostate cancer metastasis and health disparities: a systematic review

The association between sexual dysfunction and prostate cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About